Harenberg J.Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998;18:1-20.
2.
Ofosu FAPharmacological actions of sulodexide. Semin Thromb Hemost . 1998;24:127-138.
3.
Abaterusso C. , Gambaro G.The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol . 2006;5:211-222.
4.
Lauver DA, Lucchesi BRSulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006;24: 214-226.
5.
Borawski J., Dubowski M., Pawlak K., Mysliwiec M.Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007;558:167-171.
6.
Gozdzikiewicz J., Borawski J., Mysliwiec M.Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost. 2009. doi:10.1177/ 1076029607304722. Already published 2009;15:92-97.
7.
Borawski J., Dubowski M., Pawlak K., Mysliwiec M.Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers. Clin Appl Thromb Hemost. 2008 doi:10.1177/1076029608326170.
8.
Eichinger S. , Wolz M., Nieszpaur-Los M., et al. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost. 1994;72: 831-835.
9.
Amelsberg A. , Zurborn KH, Gartner U., Kiehne KH, Preusse AK, Bruhn HDInfluence of heparin treatment on biochemical markers of an activation of the coagulation system . Thromb Res. 1992;66:121-131.
10.
He L., Giri TK, Vicente CP, Tollefsen DMVascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood. 2008;111:4118-4125.
11.
Chuang YJ, Swanson R., Raja SM, Olson STHeparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin . J Biol Chem. 2001;276:14961-14967.
12.
van der Putten RFM , Glatz JFC, Hermens WTPlasma markers of activated hemostasis in the early diagnosis of acute coronary syndrome . Clin Chim Acta. 2006;371: 37-54.
13.
Brack MJ, More RS, Hubner PJ, Gershlick AHProthrombin fragment F1+2 concentrations for monitoring anticoagulation therapy with heparin. Int J Cardiol. 1993;38:57.
14.
Feinberg WM , Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke . 1997;28:1101-1106.
15.
Linhardt RJ , al-Hakim A., Liu JA, et al. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol. 1991;42:1609-1619.
16.
Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JIMolecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin . J Biol Chem. 2001;276:20959-20965.
